Literature DB >> 11815254

Age-related mutation accumulation at a lacZ reporter locus in normal and tumor tissues of Trp53-deficient mice.

Heidi Giese1, Wendy K Snyder, Conny van Oostrom, Harry van Steeg, Martijn E T Dollé, Jan Vijg.   

Abstract

Increased genomic instability has been found associated with cancer and aging. The p53 tumor suppressor protein is a major determinant of genomic instability as a regulator of cell cycle control and apoptosis in response to DNA damage. To investigate the rate of age-related mutation accumulation in the absence of p53, we crossed Trp53 null mice with transgenic mice harboring a lacZ mutational target gene. In the hybrid animals, lacZ mutation frequencies at early age (i.e. at about 2 months) were found to be the same as in the control lacZ animals. However, up until about 6 months, when the Trp53-knockout mice usually die from cancer, mutations were found to accumulate with age in the spleen, and to a lesser extent in the liver, at a more rapid rate than in the control Trp53(+/+) or Trp53(+/-), lacZ hybrid mice. Treatment of 2-3-month-old Trp53(-/-), lacZ hybrid mice with the powerful mutagen ethyl nitrosourea (ENU) resulted in a higher number of mutations induced in the liver but not in the spleen, as compared to the Trp53(+/+), lacZ mice. These results suggest that p53 is not an important determinant of gene mutation induction, either spontaneously during development or after treatment with a mutagen. The accelerated age-related accumulation of mutations in normal spleen and liver could be explained by the defect in apoptosis, which would prevent severely damaged cells from being eliminated.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11815254     DOI: 10.1016/s1383-5718(01)00329-1

Source DB:  PubMed          Journal:  Mutat Res        ISSN: 0027-5107            Impact factor:   2.433


  10 in total

Review 1.  Epigenetic factors in aging and longevity.

Authors:  Silvia Gravina; Jan Vijg
Journal:  Pflugers Arch       Date:  2009-09-19       Impact factor: 3.657

2.  The Sweet Pee model for Sglt2 mutation.

Authors:  Joseph P Ly; Tuncer Onay; Karen Sison; Gavasker Sivaskandarajah; Venkata Sabbisetti; Lingli Li; Joseph V Bonventre; Ann Flenniken; Neal Paragas; Jon M Barasch; S Lee Adamson; Lucy Osborne; Janet Rossant; Jurgen Schnermann; Susan E Quaggin
Journal:  J Am Soc Nephrol       Date:  2011-01       Impact factor: 10.121

3.  Toward an evolutionary model of cancer: Considering the mechanisms that govern the fate of somatic mutations.

Authors:  Andrii I Rozhok; James DeGregori
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-21       Impact factor: 11.205

Review 4.  Challenging the axiom: does the occurrence of oncogenic mutations truly limit cancer development with age?

Authors:  J DeGregori
Journal:  Oncogene       Date:  2012-07-02       Impact factor: 9.867

5.  Modeling variation in tumors in vivo.

Authors:  James R Stringer; Jon S Larson; Jared M Fischer; Mario Medvedovic; Megan N Hersh; Gregory P Boivin; Saundra L Stringer
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-03       Impact factor: 11.205

Review 6.  Stem Cell DNA Damage and Genome Mutation in the Context of Aging and Cancer Initiation.

Authors:  Lara Al Zouabi; Allison J Bardin
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-10-01       Impact factor: 9.708

7.  Stochastic modeling indicates that aging and somatic evolution in the hematopoetic system are driven by non-cell-autonomous processes.

Authors:  Andrii I Rozhok; Jennifer L Salstrom; James DeGregori
Journal:  Aging (Albany NY)       Date:  2014-12       Impact factor: 5.682

8.  A generalized theory of age-dependent carcinogenesis.

Authors:  Andrii Rozhok; James DeGregori
Journal:  Elife       Date:  2019-04-29       Impact factor: 8.140

9.  Somatic maintenance impacts the evolution of mutation rate.

Authors:  Andrii Rozhok; James DeGregori
Journal:  BMC Evol Biol       Date:  2019-08-23       Impact factor: 3.260

10.  Single-cell analysis of somatic mutation burden in mammary epithelial cells of pathogenic BRCA1/2 mutation carriers.

Authors:  Shixiang Sun; Kristina Brazhnik; Moonsook Lee; Alexander Y Maslov; Yi Zhang; Zhenqiu Huang; Susan Klugman; Ben H Park; Jan Vijg; Cristina Montagna
Journal:  J Clin Invest       Date:  2022-03-01       Impact factor: 14.808

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.